Dr. Thomas F. Miller is Vice President & Global Head, Pediatric Development for Bayer’s Pharmaceutical Division, a role he assumed in 2017. In total, Dr. Miller’s career in the life science industry spans more than 25 years, with a primary focus on the development of therapeutics, medical devices, and combination products for infirmed children.

He is classically trained in physiology and pharmacology with a primary interest in translational and clinical research for pediatric critical care patients. Prior to joining Bayer, Dr. Miller served in the capacity of Chief Executive Officer of Therabron Therapeutics, Inc. with oversight of all operational functions for the company (R&D, manufacturing, quality, regulatory affairs, etc.). While at Therabron, he oversaw their clinical program through Phase 2 completion for their lead molecule (orphan pediatric disease) and secured both the Rare Pediatric Disease and Fast Track designations for this program. Prior to Therabron, Dr. Miller served in the capacity of Chief Operating Officer of Discovery Laboratories, Inc. During his tenure, the company successfully secured marketing authorization for their first approved therapeutic (rare pediatric disease), successfully registered their first medical device (pediatric drug delivery enabling technology), and advanced multiple pediatric-centric pipeline programs into the clinic. Earlier, Dr. Miller served in operational roles of increasing responsibility at Pfizer, Novartis, BASF Pharma, and Johnson & Johnson. He has authored several peer-reviewed publications, given numerous presentations at scientific symposia and is an inventor with an issued patent in the field of pediatric respiratory drug delivery.